Company-wide revenue
Reported revenue in 2021 ¥76.03B Reported revenue in 2025 ¥76.87B
- growth amount
- +¥837M
- growth annualized
- +0.3%
- growth total
- +1.1%
Japanese company profile · 4521
KAKEN PHARMACEUTIAL CO., LTD.
In its FY2025 public filing, KAKEN PHARMACEUTIAL CO., LTD. reports Pharmaceuticals, Real Estate. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 科研製薬株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
KAKEN PHARMACEUTIAL CO., LTD.'s largest reported business by revenue in FY2025 was Pharmaceuticals.
The business with the highest reported segment profit in FY2025 was Real Estate.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Pharmaceuticals | ¥74.33B ↗ | 96.7% | −¥2.28B ↗ |
| Real Estate | ¥2.54B ↗ | 3.3% | ¥1.38B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Pharmaceuticals
- 薬業
- Real Estate
- 不動産事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Pharmaceuticals
- 薬業
- Real Estate
- 不動産事業
- Sales
- 売上高
- Operating profit
- 営業利益
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Pharmaceuticals | ¥73.62B | ¥70.56B | ¥69.61B | ¥91.55B | ¥74.33B |
| Real Estate | ¥2.41B | ¥2.42B | ¥2.43B | ¥2.48B | ¥2.54B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Pharmaceuticals
Reported revenue in 2021 ¥73.62B Reported revenue in 2025 ¥74.33B
- growth amount
- +¥705M
- growth total
- +1.0%
View original filing
Real Estate
Reported revenue in 2021 ¥2.41B Reported revenue in 2025 ¥2.54B
- growth amount
- +¥133M
- growth annualized
- +1.4%
- growth total
- +5.5%
View original filing
Real Estate
Reported profit margin in 2022 +53.3%
Reported profit margin in 2025 +54.1%
- growth margin points
- +0.9
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YK2Q
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.